Abstract: Multiple sclerosis (MS) is a chronic, immune-mediated demyelinating disease of the central nervous system. Animal models of MS have been critical for elucidating MS pathological mechanisms and how they may be targeted for therapeutic intervention. Here we review the most commonly used animal models of MS. Although these animal models cannot fully replicate the MS disease course, a number of models have been developed to recapitulate certain stages. Experimental autoimmune encephalomyelitis (EAE) has been used to explore neuroinflammatory mechanisms and toxin-induced demyelinating models to further our understanding of oligodendrocyte biology, demyelination and remyelination. Zebrafish models of MS are emerging as a useful research tool to validate potential therapeutic candidates due to their rapid development and amenability to genetic manipulation.
Introduction
Multiple sclerosis epidemiology and disease course Multiple sclerosis (MS) is an autoimmune disease, with targeted myelin attack that causes demyelination, followed by neuronal loss that manifests clinically as impairments in the motor, visual, sensory and autonomic systems. 1 See Thompson et al. 2 for a comprehensive review.
Both genetic and environmental factors contribute towards disease development; however, aetiology is complex and not fully understood. Animal models of MS have contributed towards significant advances in our understanding of MS pathogenesis. Continuing efforts aim to elucidate further the complex mechanisms and therefore how they could be targeted for therapeutic intervention.
Rationale for animal models
The living system is incredibly complicated. There are complex interrelations between the body's cells, tissues, organs and organ systems and subtle changes at the molecular level can have a profound impact on the organism as a whole. The complex nature of MS means that it is difficult to fully replicate the human disease using in vivo models. This said, a number of different models have been developed that can mimic certain stages of the disease course.
Experimental autoimmune encephalomyelitis
Experimental autoimmune encephalomyelitis (EAE) is the most commonly used animal model in MS research and has directly contributed towards the development of a number of first-line treatments that target the inflammatory phase of disease. 3 EAE is an induced inflammatory disease of the central nervous system (CNS), following the induction of the immune response against CNS-specific antigens.
EAE induction through active immunisation
There are two main methods of inducing EAE, namely, active EAE through immunisation with CNS peptides and passive EAE through the adoptive transfer of encephalitogenic T cells. EAE can be induced in susceptible strains using encephalitogenic peptides, such as proteolipid protein (PLP), spinal cord homogenate (SCH), myelin basic protein (MBP) and Animal models of multiple sclerosis: From rodents to zebrafish myelin oligodendrocyte glycoprotein (MOG). These peptides are usually emulsified in incomplete Freund's adjuvant (IFA) alongside mycobacterium to make complete Freund's adjuvant (CFA). The use of adjuvants aims to mimic the immune activation pathways caused by infectious agents and increase induction efficiency. 4, 5 Pertussis toxin is sometimes also used to help facilitate EAE induction by disrupting the bloodbrain barrier (BBB) integrity. 6 Immunisation results in the activation of myelin antigen-specific T cells and their subsequent proliferation and differentiation into effector T cells. The expression of integrins on these effector T cells enables them to cross the BBB. 7 Once in the CNS they are re-activated by resident myelin antigen-presenting cells (APCs) 8 which results in pro-inflammatory cytokine expression by effector T cells, namely, interferon-γ (IFN-γ), interleukin-17 (IL-17), tissue necrosis factor-α (TNF-α) and granulocyte-macrophage colony-stimulating factor (GM-CSF). Furthermore, pathogenic chemokine production recruits γδ T cells, macrophages, monocytes and neutrophils into the CNS. 9, 10 These processes are largely responsible for the destruction of the myelin sheath (Figure 1 ), which presents as ascending paralysis, starting at the tail, followed by the hindlimbs, and progressing onto the upper limbs. 11 The pathological features of the CNS lesions are typically pattern I/II lesions, dominated by T cells. 12 Disease course and strain variation EAE disease course is significantly influenced by several factors, including species, strain and the autoantigen used. Initial EAE studies used crude SCH to induce disease in mice and Rhesus monkeys. 13, 14 Further work identified specific encephalitogenic epitopes within the homogenate. One of the first to be identified was MBP in both guinea pigs 15 and certain mouse strains. 16 Further research identified other peptides that could induce disease in various murine strains, including MOG, 17, 18 myelin-associated glycoprotein (MAG), 19, 20 myelin-associated oligodendrocyte basic protein (MOBP) 21, 22 and 2′,3′-cyclic-nucleotide 3′-phosphodiesterase (CNPase). 20, 22 The numerous encephalitogenic peptides and induction methods, coupled with the wide variety of species and strains, mean that EAE induction protocols can vastly differ. This variability has been exploited to model the different disease manifestations shown in MS (Table 1) .
Mouse models. Mice are the most common species used in EAE research, which can be largely attributed to their low cost, availability of research tools and the ability to generate transgenic strains. C57BL/6 mice are one of the most popular strains used in biomedical research. C57BL/6 mice are generally considered to be EAE resistant; however, disease can be induced with MOG . Induction with 300 µg MOG results in a chronic, non-remitting disease with the first neurological deficits starting around 11-15 days post induction and no recovery up to 4 months. 18, 23 Disease onset is accompanied by infiltration of immune cells into the cortex, spinal cord and cerebellum. The presence of these infiltrates persists up to 50 days post induction. 43 Axonal loss is limited to the spinal cord; however, minimal demyelination is seen. 23 Interestingly, when a lower dose of 50 µg MOG is used to induce disease, a relapsingremitting (RR) disease course develops. These remitting mice, however, show reduced myelin loss, axonal damage and lesion burden when compared to the aforementioned chronic, non-remitting model. 44 The lack of histological hallmarks alongside the low relapsing frequency means that more robust models can be used to induce an RR disease course.
The SJL mouse is another strain frequently used for EAE induction. Induction with PLP 139-151 induces a chronic, relapsing disease course with the onset of Autoantigen-presenting dendritic cells (DCs) activate self-reactive CD4+ T cells in the periphery, resulting in their migration into the CNS. These are then re-stimulated in the CNS by resident APCs. This is followed by microglial activation and the production of cytokines and chemokines that results in the recruitment of T cells, B cells, macrophages and DCs. These infiltrating immune cells release pro-inflammatory cytokines, reactive oxygen species and complement which ultimately results in damage to the myelin sheath and manifestation of clinical symptoms. 35 Croxford et al., 36 Shin et al. 37 symptoms occurring 12-18 days post induction. 28 The first acute relapse is usually more severe than the subsequent relapses and the first relapse occurs within 10-20 days after the initial disease onset. Further relapses are highly variable and can differ in their incidence, time of onset and severity. 26, 28 This variability means that using this model can be challenging. PLP [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] is also encephalitogenic in SJL/J mice with an indistinguishable disease phenotype from PLP 139-151 -induced mice, in terms of incidence, severity and histologic features. 45 Secondary progressive EAE models have also been developed. The Biozzi ABH mouse presents an RR disease course and relapses are easy to distinguish following induction with SCH. 46 Following the RR course, Biozzi ABH mice typically slowly develop secondary progressive disease alongside marked demyelination, glial cell activation, gliosis and neuronal loss. 47 Onset of clinical signs of paralytic disease usually arises around 16 days post induction which is preceded by weight loss. Following up to three relapses, mice enter a chronic phase of the disease from which they do not recover that is characterised by demyelination, gliosis, glial cell activation and axonal and neuronal loss. 33, 48 This model offers the ability to assess potential therapeutic agents in both immunemediated and established neurodegenerative disease.
Induction in the non-obese diabetic mouse also shows a secondary progressive phenotype. Induction with MOG results in an RR disease course followed by a secondary progressive stage. The first relapse appears around day 10 which remits around day 22. Following up to three relapses, the disease moves onto a chronic progressive stage. Disease progression is characterised by demyelination, glial cell activation and axonal loss. 49 The mechanisms that contribute towards primary progressive multiple sclerosis (PPMS) development are less well characterised and may be partly due to the relatively low number of clinically relevant models. Nevertheless, a primary progressive disease course can be induced in ASW mice following the induction with MOG [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] , with the symptom onset and weight loss occurring after 1 month. Neurological scores rapidly decline after this and most mice die within 20 days. Interestingly, if MOG 92-106 is administered alongside pertussis toxin, a secondary progressive disease course is seen. 50 This shows that induction with the same peptide can induce two different disease phenotypes and highlights the complexity of the immune response in EAE.
Rat models. Lewis rats are the most popular strain of rat used in EAE research, due to their robust response to disease induction that is not dependent on the use of additional adjuvants, such as pertussis toxin. 36 The main encephalitogenic epitope is MBP 68-86 51,52 and the disease course is characterised by an acute paralytic onset starting with tail atony and subsequent hindlimb paralysis 8-12 days post induction. This is followed by spontaneous recovery that is resistant to re-induction. 37, 53 Histological examination shows mononuclear cell infiltration of the spinal cord, cerebellum and brainstem. These lesions typically show oedema and gliosis; however, demyelination is rarely seen. 38 The highly reproducible disease course means that the Lewis rat model is useful for looking at mechanisms of T cell activation and infiltration.
EAE can also be reliably induced in Dark Agouti (DA) rats using SCH, without the need for any adjuvant. Disease onset occurs around day 9-15 and is accompanied by mononuclear cell infiltration. Unlike the Lewis rat model, disease can be re-induced following remission using an SCH emulsion containing CFA, albeit at a lower severity. Interestingly, if the initial disease induction uses CFA, disease cannot be re-induced highlighting the influence of adjuvants in altering EAE pathology. 40 Non-human primate models. The pathogenic complexity of MS is not easily replicated in rodent models of EAE which emphasises the distinct immunological, genetic, developmental and environmental differences between humans and laboratory rodents. 54, 55 This can be somewhat overcome with the use of humanised mouse models which express human T cell receptors and major histocompatibility complex (MHC) proteins. [56] [57] [58] Other ways include the use of non-human primates, including the rhesus macaque and the common marmoset, to attempt to replicate the human disease.
The first marmoset EAE model was first described over 20 years ago (extensively reviewed by 't Hart and Massacesi 59 ). Induction with whole human myelin causes a 100% disease incidence and a chronic RR disease course alongside mononuclear infiltration, demyelination and reactive astrogliosis. 60 Further development through the years has resulted in models with increased disease incidence and lower variability. 41 Their outbred nature better reflects the heterogeneity seen in the MS population, although this needs to be taken into account when interpreting the data. This can be somewhat overcome using twins. 42 These marmoset models can be used in preclinical trials and are particularly useful for assessing the therapeutic potential and safety of candidate drugs. 61 Despite these obvious advantages, the ethical and economical implications of using non-human primate models mean that they are rarely used in preclinical research. 42 
Adoptive transfer
The second method for EAE induction involves the adoptive transfer of encephalitogenic T cells into naïve animals. 62, 63 One of the first studies to demonstrate the adoptive transfer method showed that the transfer of lymphocytes from immunised rats into naïve rats induced significant neuroinflammatory disease. 64 This method gives great control over disease induction and has helped shed light on the T cell mechanisms that contribute towards EAE pathogenesis. Prior to transfer, T cells can be labelled to track T cell migration patterns into the CNS during EAE 65 and their subsequent behaviour during EAE development. 66 
Spontaneous EAE
The advancement of gene editing technology has allowed the development of immunologically adapted mice to help elucidate the mechanisms behind disease induction and progression.
Transgenic C57BL/6 mice expressing MBP-specific CD4+ T cells spontaneously develop EAE at a frequency of about 14%. Furthermore, when crossed with Rag-deficient mice to prevent the expression of endogenous receptors, the resultant Rag-deficient transgenic mice develop EAE with a 100% incidence rate. 67 This was one of the first transgenic models to demonstrate that monospecific CD4+ T cells can cause EAE independently of other adaptive immune cells and that the presence of other T and B cells can regulate disease progression by preventing EAE onset. SJL/J mice that express a T cell receptor specific for MOG [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] spontaneously develop RR EAE, which is accompanied by large inflammatory and demyelinated lesions in the cerebellum and brainstem. Interestingly, when these mice are depleted of B cells using the monoclonal anti-mouse CD20 antibody, EAE is profoundly suppressed. 68 Humanised T cell receptor transgenic mice have also been developed. One of the first showed that double transgenic mice that express human MBP [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] and HLA DR15 develop spontaneous EAE which again increases when crossed with Rag-deficient mice. 69 Another humanised transgenic model is the PLP [45] [46] [47] [48] [49] [50] [51] [52] [53] CD8+ transgenic 2D1 mice which has helped elucidate the role of HLA genes in disease pathogenesis. Friese et al. 70 found that a small proportion of these transgenic mice crossed with mice expressing HLA-A3 alleles developed spontaneous EAE; however, this was suppressed when crossed with HLA-A2-expressing mice. These humanised mice, alongside more traditional models, may help increase the translation of EAE research.
Assessment of disease
Active disease has been measured in EAE using a number of different devices; however, the neurological scoring system which monitors ascending paralysis from the tail, hindlimbs and forelimbs has proved to be the most robust and reproducible method (Figure 2) . 71 There is no international standard scoring system which leaves it difficult to compare between studies and clinical assessment scales can range from 0 to 3, 72 0 to 4, 73 0 to 5 32 and 0 to 6 18 points. This has an influence on the statistical significance reported. Recent efforts have aimed to refine this clinical scoring by including other parameters such as grid walk, a righting test and a hanging test alongside a 5.5-point neurological scale. However, this study found that this system was no more sensitive than a three-point scale. 74 Understanding the behavioural changes throughout the disease course also provides an insight into the extent of CNS damage. The rotarod assessment is frequently utilised in EAE research and is used to evaluate the motor skill coordination and balance over increasing rotarod speeds. 75 Significant impairments are seen during symptomatic phases and EAE score correlates with a worse rotarod performance. 23 The open field test is another behavioural assessment that can be used to evaluate general locomotor activity and willingness to explore. A significant reduction in distance travelled, quadrant changes and number of rearings can be seen in symptomatic EAE animals when compared to control. 23 Memory dysfunction is also observed in EAE animals. MOG-induced EAE mice are unable to discriminate between a familiar and a new object, 76 indicating a lack of ability to form and retain memories.
Other observable differences have been shown in EAE models, including impaired spatial memory, 77, 78 development of allodynia 76, 79 and behavioural changes such as anxiety and depression. 80, 81 In addition, molecular and histological analysis following EAE studies provides researchers a greater insight into pathological and therapeutic mechanisms that may not be apparent through these neurological and behavioural assessments. Therefore, the use of neurological and behavioural evaluations alongside further tissue analysis is vital for detecting subtle differences following disease manipulation.
Influencing factors
The number of aforementioned variables means that the experimental conditions can widely differ between EAE studies. Variables such as species, strain, encephalitogenic peptide, age, sex, induction method and timing of dose are all factors that need to be considered. 82 Each of these contributes towards variation between studies if they are not carefully considered.
Age
Age plays a significant role in EAE susceptibility and severity. Disease induction in young Wistar rats (7 weeks) results in the commencement of neurological deficits 12-16 days post induction, from which they spontaneously recover. However, induction in middleaged rats (15 months) results in a later onset of disease with reduced clinical signs. 83 Furthermore, in the C57BL/6 MOG 35-55 mouse model, young mice develop an acute phase of EAE followed by remission, whereas middle-aged mice exhibit a severe, chronic phenotype with no subsequent recovery. 84 Age also has a significant effect on the course of EAE in Biozzi ABH mice. Induction in 8 to 12-week-old mice induces an RR EAE phase followed by a secondary progressive phase. 48 However, mice immediately develop primary progressive EAE if disease is induced in 12-month-old Biozzi ABH mice. This increase in neurological disease severity correlates with exacerbated axonal damage, increased microglial activation and increased CD3+ T cell infiltration. Furthermore, 2-week-old mice fail to develop clinical signs of EAE, 85 which may be due to lack of immune system development. 86 One of the reasons why a difference in disease progression is seen between young and old animals may be due to thymic involution which increases susceptibility to autoimmunity through the generation of fewer or deficient regulatory T cells (T regs ). 87 A similar observation is seen in MS. If disease onset begins in younger people under 30 years, the disease usually begins with an RR phase and eventually into a secondary progressive course. However, disease manifestation typically follows a primary progressive phenotype if disease onset begins in people over 40 years. 88 
Gut microbiota
The composition of commensal gut bacteria can influence the body's functions and trigger autoimmune responses. The influence of gut flora has been identified in autoimmune disorders; however, it has only recently been evidenced as triggering autoimmune disease in the CNS. Yokote et al. showed that antibiotic treatment that altered the gut microbiota reduced CNS inflammation in MOG -induced C57BL/6 mice. They attributed this to a reduction in gut Th17 cells. 89 The effect of gut microbiota composition has further been investigated in spontaneous EAE using the SJL MOG 92-106 model. Mice housed under specific pathogen-free conditions develop EAE within 3-8 months; however, mice housed under completely germ-free conditions are fully protected throughout their life and do not present with neurological deficits. 90 Research is ongoing to identify what composition of intestinal microbiota may contribute towards disease susceptibility and may provide a new target for disease modulation.
Timing of treatment
The timing of disease intervention significantly influences the effect size of the treatment. A recent study showed that out of the 450 EAE studies analysed, 48% dosed before disease induction, 22% on the day of induction and 30% after disease induction. 3 This can alter efficacy data in preclinical trials. For example, the efficacy of natalizumab is highly dependent on the treatment schedule and study design. Administration before the onset of disease results in a significant decrease in EAE score in SJL/J mice. However, administration at the time of first peak of disease only causes a mild reduction in EAE score. 91 A similar result is seen using FTY720 (fingolimod) in the Biozzi ABH mice. Prophylactic treatment starting on day 0 completely inhibits the development of disease. However, FTY720 has no effect on disease development if treatment is started 10 days post induction. Furthermore, FTY720 fails to improve clinical disease or prevent progression if administered during the secondary progressive phase of disease (128 days post induction). 32 Thus, choosing the correct time of therapeutic intervention is an important factor to consider when considering translation.
Translation between EAE and MS studiessuccesses and failures
The most convincing evidence that EAE studies translate to the clinic come from those drugs that are currently approved, signifying the importance of this model in preclinical research (Table 2) . However, despite these successes, there have been numerous examples of where translation has not been successful. One of the main examples comes from the role of TNF-α in EAE and MS. TNF-α expression correlates with MS severity 92 and inhibition of TNF-α signalling improves disease course in a rat model of EAE. 93 However, clinical trials of TNF-α blocker infliximab worsens MS patient symptoms. 94 These failures have drawn criticism of the model and questioned the validity of EAE to effectively replicate the human disease. 95 However, these limitations are seen throughout animal research and the exact human condition is very difficult to achieve in animals.
In order to increase translation, it is imperative to maintain both internal and external validity when designing these studies. A systematic review that analysed 1117 EAE studies between 1961 and May 2008 found that only 9% included randomisation, 10% included blinded assessment of outcome and less than 1% included power calculations. Notably, studies that included both blinding and randomisation reported a significantly lower estimation of efficacy. 3 Implementing good experimental practice as well as carefully considered experimental design is critical for increasing the quality of EAE research. These practices should be outlined prior to the study commencing to reduce the risk of bias and increase experimental reliability. These efforts alongside continuing to refine the animal models will ultimately aid to bridge this gap from bench to bedside.
Toxin-induced demyelinating models

Cuprizone-induced demyelination
The cuprizone (bis-cyclohexanone oxaldihydrazone) model is a model of demyelination and remyelination that has been utilised to tease apart the specific mechanisms that contribute towards oligodendrocyte death, oligodendrocyte precursor cell (OPC) migration, differentiation and remyelination. Cuprizone-induced demyelination was first described in the late 1960s using Swiss mice. 119 Protocols now widely use C57BL/6 mice; however, methods have also been developed for rats, which are particularly useful for imaging studies due to their larger brain size. 120 Cuprizone causes specific oligodendrocyte death and subsequent demyelination; however, the mechanism is not fully known. Cuprizone is a copper ion (Cu2+) chelator and may cause oligodendrocyte death by disturbing cellular metabolism. Mega-mitochondria are observed in the liver of mice following cuprizone intoxication. 121 The presence of these mega-mitochondria indicates a disturbance in metabolic function that ultimately results in oligodendrocyte death. The resultant lesions are characteristic of pattern III and Biozzi ABH Spinal cord homogenate Intraperitoneal injection 1-2 days before EAE onset fails to prevent development Direct injection into the CNS at this time point mostly prevents EAE development Baker et al. 106 Biozzi ABH, SCH SJL/J, MBP Prevents the development of any signs of disease After acute disease prevents the incidence of relapse
Watson et al. 107 Lewis rats MBP Suppresses hindlimb paralysis Delay in progression to clinical disability and in onset of relapse Yu et al. 110 SWXJ PLP [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] Gene-based intramuscular interferon-beta therapy inhibits disease progression and reduces relapses Jaini et al. 111 C57BL/6 or muMT (B cell deficient) MOG Reduces clinical scores in C57BL/6 mice Not effective in muMT mice Robert et al. 112 Lewis rats Adoptive transfer of MBP-specific
T cells Rapid non-apoptotic termination of T Cell infiltration
Schmidt et al. 113 Biozzi IV lesions, which are associated with oligodendrocyte dystrophy and apoptosis. 12 The dose of cuprizone needed is dependent on the strain, age and sex of the mouse. Cuprizone is mixed with the chow at a concentration of 0.2%-0.6% (w/w) for 6 weeks to induce extensive demyelination throughout the brain, of which the corpus callosum is the most widely studied. 122 Intoxication in SJL mice results in a different demyelinating pattern than that seen in C57BL/6 mice. This is further influenced by gender. 123 Mice present with a timedependent weight loss and significant behavioural and motor deficiencies. 124 
Lysophosphatidylcholine-induced demyelination
Another toxin-induced model of demyelination uses the direct focal injection of lysophosphatidylcholine (LPC). LPC is specifically toxic to myelinating oligodendrocytes, while neuronal axons remain intact. LPC has a specific affinity for myelin proteins causing myelin lamellae to fuse, transform into spherical vesicles and progressively reduce in size until they are eventually phagocytosed. 125, 126 Following the injection of 1% lysolecithin into the spinal cord white matter, pathology is characterised by macrophage/ microglial infiltration, reactive astrogliosis, axonal injury and OPC proliferation/migration. 127 This is followed by spontaneous remyelination that is complete around 23 days post injection. 128 This model offers the distinct advantage of having spatial and temporal control over demyelination, and thus this model is used to interrogate the complex mechanisms of remyelination. 127
Zebrafish models of MS
Zebrafish are emerging as an exciting novel animal model for many neurodegenerative diseases, including MS and other demyelinating diseases. [129] [130] [131] Zebrafish generate large numbers of embryos, develop rapidly and are optically clear and amenable to genetic manipulation. This makes them excellent model systems for investigating neurological disorders and developing high-throughput drug screens, something not possible in current in vivo models ( Figure 3 ).
The zebrafish CNS is a simplified version of the mammalian nervous system and contains the majority of the cell types, connections and structures of the mammalian brain and spinal cord. Zebrafish myelin is deposited by oligodendrocytes in a highly regulated and controlled regime, forming tight concentric wraps around the axons as is seen in mammals. 132 Zebrafish mbp mRNA is detectable from 2 days post fertilisation by in situ hybridisation and is detectable by electron microscopy from 3 days post fertilisation. 133, 134 The majority of myelin and oligodendrocyte genes are highly conserved in the zebrafish; however, there are some differences. The major protein in zebrafish myelin is P0, rather than PLP. 135, 136 Zebrafish are emerging as an excellent model for looking at the cell-cell interactions during myelination. Using different genetic mutants and transgenic reporter lines, it is possible to visualise the processes of myelination and demyelination in real time. These zebrafish models have been used to identify some interesting insights into the mechanisms of myelination including linking neuronal subtype and axonal length to myelination characteristics and showing that oligodendrocytes still develop, even in the absence of axons. [137] [138] [139] Figure 3. Toxin-induced demyelination in zebrafish. Black gold II staining, a myelin-specific marker, shows significant demyelination in 10-day-post-fertilised zebrafish brain sections following toxin-induced demyelination. The large number of embryos generated, rapid development and their amenability to genetic manipulation mean that zebrafish are becoming a significant research tool for neurodegenerative diseases.
The majority of work undertaken so far using zebrafish as a model has focused on investigating the mechanisms of remyelination and OPC differentiation, using toxin-induced demyelination models and genetic cell ablation models. LPC exposure has been used to induce demyelination in adult zebrafish (4-7 months of age), as has been performed in murine models. 130 In this study, adult zebrafish eyes were surgically separated from the socket and LPC-soaked beads were placed next to the optic nerve. These zebrafish showed focal demyelination of the optic nerve, microglial influx and reduction of Olig2+ cells within 8 days of LPC exposure. Remyelination, resolution of the microglial response and recovery of oligodendrocytes are seen at 28 days post surgery highlighting the speed of remyelination in zebrafish. During the demyelination and remyelination, no reduction in the number of axons is seen, highlighting that this model shows specific toxicity to oligodendrocytes and myelin, opposed to widespread cellular toxicity. Interestingly, the recovery of all these disease mechanisms took far longer in aged zebrafish (>15 months old) with myelin never fully recovering, even 3 months after the toxin-induced demyelination.
They also see a reduced microglial response in the older zebrafish, a possible reason why remyelination in older zebrafish is less effective. This model has the potential to be very effective for investigating the mechanisms of remyelination, separate from the inflammatory aspect of disease, and recapitulates all of the mechanisms of the aforementioned murine toxin-induced demyelination models. Using this model, it will be interesting to look at how genetic manipulation can alter and accelerate remyelination. Unfortunately, this model requires surgery and a relatively long time for recovery making its applicability for drug screening limited, but would be a powerful tool to validate potential therapeutics from primary screens.
A genetic inducible demyelination model has also been generated by the ablation of oligodendrocytes and thus removal of myelin. This was generated using a nitroreductase/metronidazole system expressed under the control of the mbp and sox10 promoter. 140 This system allows the inducible ablation of the entire oligodendrocyte population and CNS demyelination occurs within 48 hours of metronidazole administration. They showed that they could induce demyelination in both larval and adult zebrafish and see demyelination within 12 hours to 2 days with recovery 1 week later. These models have been used to screen therapeutics that could accelerate remyelination. Zebrafish treated with sulfasalazine, an immunomodulatory drug, increased cellular proliferation, accelerated remyelination and reduced the immune response. 129 This genetic model is advantageous in screening for therapeutics that promote remyelination, but questions remain over its applicability as a disease model, especially as complete ablation of the oligodendrocyte population is not a common MS mechanism.
More recently an EAE zebrafish model has been developed for developing rapid screens in vivo. 141 Adult zebrafish were subcutaneously injected with MOG near the spinal vertebrae, resulting in disability/paralysis, reduced body weight, microglial influx and reduced survival. The advantage of the zebrafish as an EAE model is how rapidly the clinical symptoms are induced with a detectable disease phenotype at 3 days post immunisation and significant impairment at 7 days post fertilisation. In this study, they went on to validate the possibility of using this model as a screening tool showing that treatment with fingolimod, dexamethasone and dimethyl fumarate reduced the EAE effects in a dose-dependent manner. This model has the potential to be highly useful as a primary in vivo screening tool to triage drugs before screening in rodent EAE models, which is ultimately much longer and more expensive. 142, 143 Further work is required to validate and understand this model as MOG has not currently been identified in the zebrafish genome, so it is imperative to identify what is driving the autoimmunity. Also, further clarification of myelin loss by electron microscopy and specific myelin antibodies would be a useful readout for drug effect and confirmation of EAE.
Zebrafish are emerging as a useful model for the study of MS. The similarities in myelin and oligodendrocyte biology, alongside the rapid development and large numbers available, give them potential to be used as an excellent model for in vivo screening for pro-myelinating therapeutics. Currently, zebrafish models are at an early stage of development and the primary advantages of zebrafish models are on the characterisation of the mechanisms of demyelination and remyelination. Further work on the immune system involvement in the modulation of demyelination would be required to ascertain the strengths and weaknesses of zebrafish models in MS research. However, it is important to understand that zebrafish immune system does not mimic the mammalian system and care should be noted in designing studies that examine the role of immune system in the zebrafish model of MS. The ultimate goal in the future is for zebrafish models to be used as a preclinical screening tool to triage compounds in drug screens prior to screening in higher models.
Concluding remarks
Animal models of MS have provided a useful platform for evaluating MS pathogenesis and how this may be targeted for therapy. Although the EAE model does not directly resemble MS, a number of models have been developed to recapitulate the disease manifestations. Toxin-induced demyelinating models provide a platform to study the cellular mechanisms of demyelination and remyelination. The recent development of novel zebrafish models provides a novel tool for screening of potential therapeutics and to gain further understanding of pathological mechanisms.
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